Edoxaban: Impact on routine and specific coagulation assays

Summary

Assessment of plasma concentration/effect of edoxaban may be useful in some situations. Also, clinicians need to know how routine coagulation assays are influenced. It was our aim to determine coagulation tests useful for the assessment of edoxaban’s pharmacodynamics and provide recommendations for the interpretation of haemostasis diagnostic tests. Edoxaban was spiked at concentrations ranging from 0 to 1,000 ng/ml in platelet-poor plasma which covers the on-therapy range (from ± 25 ng/ml at C_trough to ± 170 ng/ml at C_max). aPTT, PT, dRVVT, chromogenic anti-Xa assays, TGA and a large panel of haemostasis diagnostic tests were performed using several reagents. A concentration-dependent prolongation of aPTT, PT and dRVVT was observed. The effect was dependent on the reagents. FXa chromogenic assays showed high sensitivity and a linear correlation depending on the methodology. TGA may be useful to assess the pharmacodynamics of edoxaban but its turnaround time and the lack of standardisation are limitations. Edoxaban impairs the assessment of lupus anticoagulant, protein S (clotting method), APC-R, antithrombin (FXa-based assay) and measurement of clotting factor activity. Immunological assays and assays acting below the FXa are not influenced by edoxaban. In conclusion, some PT reagents could be used to estimate edoxaban activity. Chromogenic anti-Xa assays are required to assess the plasma concentration. TGA may be useful but requires standardisation. In case of thrombophilia or in the exploration of a haemorrhagic event, immunological assays should be recommended, when applicable. Standardisation of the time between the last intake and the sampling is mandatory to provide a proper assessment of the result.

Supplementary Material to this article is available online at www.thrombosis-online.com.

Keywords

Edoxaban - drug measurement - coagulation tests - guidelines - factor Xa inhibitors

^* Contributed equally as last authors.

• References

• 1 Giugliano RP, Ruff CT, Braunwald E. et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093-2104.
• 2 Hokusai VTEI, Buller HR, Decousus H. et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369: 1406-1415.
• 3 Raskob G, Cohen AT, Eriksson BI. et al. Oral direct factor Xa inhibition with ed-oxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study. Thromb Haemost 2010; 104: 642-649.
• 4 Ruff CT, Giugliano RP, Braunwald E. et al. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet. 2015 Epub ahead of print.
• 5 Daiichi Sankyo, Inc.. Highlights of Prescribing Information - Savaysa. [Internet Document from FDA Website]. Daiichi Sankyo / U.S. Food and Drug Administration; 01.2015 [cited 2015 June 11]. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206316lbl.pdf
• 6 Parasrampuria DA, Marbury T, Matsushima N. et al. Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing hae-modialysis. Thromb Haemost 2015; 113: 719-727.
• 7 Patel MR, Mahaffey KW, Garg J. et al. Rivaroxaban versus warfarin in nonvalvu-lar atrial fibrillation. N Engl J Med 2011; 365: 883-891.
• 8 Granger CB, Alexander JH, McMurray JJ. et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-992.
• 9 Weitz JI, Connolly SJ, Patel I. et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost 2010; 104: 633-641.
• 10 Douxfils J, Mullier F, Dogne JM. Dose tailoring of dabigatran etexilate: obvious or excessive?. Expert Opin Drug Saf 2015; 1-7.
• 11 Food and Drug Administration. Xarelto - Clinical Pharmacology and Biophar-maceutics Review(s). Available at: http://www.accessdata.fda.gov/drug/satfda_docs/nda/2011/022406Orig1s000ClinPharmR.pdf Accessed April 18, 2015.
• 12 Food and Drug Administration. Eliquis - Clinical Pharmacology and Biophar-maceuticsReview(s). Available at: http://www.accessdata.fda.gov/drug/satfda_docs/nda/2012/202155Orig1s000ClinPharmR.pdf Accessed May 5, 2015.
• 13 Dincq AS, Lessire S, Douxfils J. et al. Management of non-vitamin K antagonist oral anticoagulants in the perioperative setting. Biomed Res Int 2014; 2014: 385014.
• 14 Mendell J, Noveck RJ, Shi M. A randomized trial of the safety, pharmacokinetics and pharmacodynamics of edoxaban, an oral factor Xa inhibitor, following a switch from warfarin. Br J Clin Pharmacol 2013; 75: 966-978.
• 15 Zahir H, Matsushima N, Halim AB. et al. Edoxaban administration following enoxaparin: a pharmacodynamic, pharmacokinetic, and tolerability assessment in human subjects. Thromb Haemost 2012; 108: 166-175.
• 16 Camici GG, Steffel J, Akhmedov A. et al. Dimethyl sulfoxide inhibits tissue factor expression, thrombus formation, and vascular smooth muscle cell activation: a potential treatment strategy for drug-eluting stents. Circulation 2006; 114: 1512-1521.
• 17 Douxfils J, Chatelain C, Chatelain B. et al. Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide. Thromb Haemost 2013; 110: 283-294.
• 18 Douxfils J, Mullier F, Loosen C. et al. Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of riva-roxaban and review of the literature. Thromb Res 2012; 130: 956-966.
• 19 Douxfils J, Mullier F, Robert S. et al. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost 2012; 107: 985-997.
• 20 Mani H, Hesse C, Stratmann G. et al. Ex vivo effects of low-dose rivaroxaban on specific coagulation assays and coagulation factor activities in patients under real life conditions. Thromb Haemost 2013; 109: 127-136.
• 21 Mani H, Hesse C, Stratmann G. et al. Rivaroxaban differentially influences ex vivo global coagulation assays based on the administration time. Thromb Hae-most 2011; 106: 156-164.
• 22 Freyburger G, Macouillard G, Labrouche S. et al. Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement. Thromb Res 2011; 127: 457-465.
• 23 Food and Drug Administration. Savaysa - Clinical Pharmacology and Biophar-maceuticsReview(s). Available at. http://www.accessdata.fda.gov/drug/satfda_docs/nda/2015/206316Orig1Orig2s000ClinPharmR.pdf Accessed June 12, 2015.
• 24 Cuker A, Husseinzadeh H. Laboratory measurement of the anticoagulant activity of edoxaban: a systematic review. J Thromb Thrombol 2015; 39: 288-294.
• 25 Douxfils J, Dogne JM, Mullier F. et al. Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate. Thromb Haemost 2013; 110: 543-549.
• 26 Douxfils J, Tamigniau A, Chatelain B. et al. Comparison of calibrated chromo-genic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban. Thromb Haemost 2013; 110: 723-731.
• 27 Hawes EM, Deal AM, Funk-Adcock D. et al. Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacody-namic study based on peak and trough plasma levels. J Thromb Haemost 2013; 11: 1493-1502.
• 28 Francart SJ, Hawes EM, Deal AM. et al. Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels. Thromb Haemost 2014; 111: 1133-1140.
• 29 Gosselin RC, Adcock Funk DM, Taylor JM. et al. Comparison of anti-xa and dilute russell viper venom time assays in quantifying drug levels in patients on therapeutic doses of rivaroxaban. Arch Pathol Lab Med 2014; 138: 1680-1684.
• 30 Bathala MS, Masumoto H, Oguma T. et al. Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans. Drug Metabol Disposit 2012; 40: 2250-2255.
• 31 Van Blerk M, Bailleul E, Chatelain B. et al. Influence of dabigatran and riva-roxaban on routine coagulation assays. A nationwide Belgian survey. Thromb Haemost 2015; 113: 154-164.
• 32 Gouin-Thibault I, Flaujac C, Delavenne X. et al. Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. A multicentre French GEHT study. Thromb Haemost 2014; 111: 240-248.
• 33 Samama MM, Contant G, Spiro TE. et al. Evaluation of the prothrombin time for measuring rivaroxaban plasma concentrations using calibrators and controls: results of a multicenter field trial. Clin Appl Thromb Hemost 2012; 18: 150-158.
• 34 Samama MM, Contant G, Spiro TE. et al. Evaluation of the anti-factor Xa chro-mogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost 2012; 107: 379-387.
• 35 Asmis LM, Alberio L, Angelillo-Scherrer A. et al. Rivaroxaban: Quantification by anti-FXa assay and influence on coagulation tests: a study in 9 Swiss laboratories. Thromb Res 2012; 129: 492-498.
• 36 Baglin T, Hillarp A, Tripodi A. et al. Measuring Oral Direct Inhibitors (ODIs) of thrombin and factor Xa: A recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2013; 11: 756-760.
• 37 Douxfils J, Tamigniau A, Chatelain B. et al. Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays. Thromb J 2014; 12: 24.
• 38 Furugohri T, Isobe K, Honda Y. et al. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J Thromb Haemost 2008; 06: 1542-1549.
• 39 Zafar MU, Vorchheimer DA, Gaztanaga J. et al. Antithrombotic effects of factor Xa inhibition with DU-176b: Phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber. Thromb Haemost 2007; 98: 883-888.
• 40 Barrett YC, Wang Z, Frost C. et al. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost 2010; 104: 1263-1271.
• 41 Harenberg J, Kramer R, Giese C. et al. Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays: reduction of interassay variability. J Thromb Thrombol 2011; 32: 267-271.
• 42 Samama MM, Amiral J, Guinet C. et al. An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma. Thromb Haemost 2010; 104: 1078-1079.
• 43 Douxfils J, Lessire S, Dincq AS. et al. Estimation of dabigatran plasma concentrations in the perioperative setting. An ex vivo study using dedicated coagulation assays. Thromb Haemost 2015; 113: 862-869.
• 44 Gerotziafas GT, Baccouche H, Sassi M. et al. Optimisation of the assays for the measurement of clotting factor activity in the presence of rivaroxaban. Thromb Res 2012; 129: 101-103.
• 45 van Os GM, de Laat B, Kamphuisen PW. et al. Detection of lupus anticoagulant in the presence of rivaroxaban using Taipan snake venom time. J Thromb Hae-most 2011; 09: 1657-1659.
• 46 Robert S, Ghiotto J, Pirotte B. et al. Is thrombin generation the new rapid, reliable and relevant pharmacological tool for the development of anticoagulant drugs?. Pharmacol Res 2009; 59: 160-166.
• 47 Morishima Y, Kamisato C. Laboratory measurements of the oral direct factor Xa inhibitor edoxaban: comparison of prothrombin time, activated partial throm-boplastin time, and thrombin generation assay. Am J Clin Pathol 2015; 143: 241-247.
• 48 Perrin J, Depasse F, Lecompte T. et al. Large external quality assessment survey on thrombin generation with CAT: further evidence for the usefulness of normalisation with an external reference plasma. Thromb Res 2015; 136: 125-130.
• 49 Marlu R, Hodaj E, Paris A. et al. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 2012; 108: 217-224.
• 50 Honickel M, Treutler S, van Ryn J. et al. Reversal of dabigatran anticoagulation ex vivo: Porcine study comparing prothrombin complex concentrates and ida-rucizumab. Thromb Haemost 2015; 113: 728-740.
• 51 Greinacher A, Thiele T, Selleng K. Reversal of anticoagulants: an overview of current developments. Thromb Haemost 2015; 113: 931-942.
• 52 Escolar G, Fernandez-Gallego V, Arellano-Rodrigo E. et al. Reversal of apixaban induced alterations in hemostasis by different coagulation factor concentrates: significance of studies in vitro with circulating human blood. PloS one 2013; 08: e78696.
• 53 Martin AC, Gouin-Thibault I, Siguret V. et al. Multimodal assessment of nonspecific hemostatic agents for apixaban reversal. J Thromb Haemost. 2015 Epub ahead of print.
• 54 Eerenberg ES, Kamphuisen PW, Sijpkens MK. et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124: 1573-1579.